Which trial compared the effectiveness of Watchman versus warfarin for stroke risk reduction?

The correct answer is that both the PREVAIL and Protect AF trials compared the effectiveness of the Watchman device versus warfarin in reducing stroke risk in patients with atrial fibrillation. These trials are significant as they contributed to the understanding of the safety and efficacy of the Watchman device as an alternative method for preventing thromboembolic strokes, particularly for patients who are at high risk for such complications but may not be good candidates for long-term anticoagulation therapy.

The Protect AF trial primarily established the initial safety and effectiveness of the Watchman device, showing that it could reduce the risk of stroke similarly to warfarin while also having a favorable safety profile. Following this, the PREVAIL trial further investigated its use, including a larger sample size and longer follow-up, to reinforce these findings and gather additional data on its performance.

Together, these trials provided a comprehensive evaluation of the Watchman device against warfarin, supporting its role in clinical practice for specific patient populations. Thus, recognizing both trials is crucial for understanding the development of LAA occlusion strategies in managing atrial fibrillation and preventing strokes.